
|Articles|September 15, 2004
Six-month clinical results positive for dual-optic IOL
San Diego-First trial results with the Synchrony dual-optic accommodative IOL (Visiogen Inc.) indicate that this first-generation lens is safe and performs well. However, lens power calculations should improve via more IOL implantation and calculation adjustment, according to Gerd Auffarth, MD.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA approves carbachol–brimonidine eye drop for presbyopia following phase 3 BRIO trials
2
MacTel Decoded: Rethinking Conventional Approaches with Novel Neuroprotective Strategies
3
When Mites Meet Their Match: Empowering Patients With Targeted Treatment for Demodex Blepharitis
4
Study finds artificial tear viscosity and shear-thinning behavior vary by formulation
5



























